A variation to the clinical staging of AD was proposed by the National Institute on Aging – Alzheimer’s Association (NIA-AA) working group (2018) using six clinical stages for persons who are amyloid positive.
The NIA-AA Research Framework describes AD as a biological construct that can be identified in living persons via Aβ and tau biomarkers.
In the NIA-AA framework, biomarkers are used to identify the presence of AD, with clinical stages used to indicate disease severity.
Read more about New clinical staging of Alzheimer’s disease
Related content
Stroke, migraine, Alzheimer’s Disease and other dementias were among the top ten conditions that accounted for the greatest nervous system DALYs in 2021
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease and the leading cause of dementia worldwide, regardless of socioeconomic status.
Dementia is an umbrella term used to describe a state where an individual has lost the ability to carry out daily life activities independently because of cognitive impairment that is not due to an underlying psychiatric condition. Alzheimer’s disease (AD) refers to the abnormal presence of Aβ and tau proteins, which define AD among many other neurodegenerative diseases. Dementia -including dementia due to AD- is likely to be underestimated because of underdiagnosis and misdiagnosis.